💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, trading cheap versus its own history.
Eris Lifesciences is scored on the pharma / healthcare framework. It keeps a fat 20.6% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.83×). Free cash flow is worth about 1.0% of its market value.
Over the last 3 years revenue compounded at 23%/yr and profit at 20%/yr. Book value itself has compounded 21%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 17.1%. In the latest quarter profit fell 49% versus the prior quarter.
At 27× earnings, the stock sits at the 12th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~11%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 23.79 | — | — |
| P/B | 4.12 | 4.1 | worse |
| EV/EBITDA | 17.28 | 19.33 | better |
| ROE | 17.07 | — | — |
| ROCE | 12.58 | 14.41 | worse |
| ROA | 9.48 | 1.64 | better |
| Quick Ratio | 0.53 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 23% CAGR over 3 years — high-growth territory. Growth is decelerating — latest year grew slower than the year before.
The latest year saw a +73% swing — check if it's a one-off or structural.
Operating margin has compressed from 24% to 20% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line. Margins have declined for 2 consecutive years — watch for a structural cost problem.
ROE at 17% — a respectable return on shareholder capital. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power.
Profit grew faster than EPS (20% vs 17%) — share dilution is eroding per-share value. 17% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 15% sequentially — momentum is building.
Profit fell 49% QoQ — one-quarter drops can be noise, but a pattern matters.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 54.7% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.